Seeking Alpha

Perrigo (PRGO +0.5%) announces final FDA approval for its Ketoconazole Foam 2% treatment for...

Perrigo (PRGO +0.5%) announces final FDA approval for its Ketoconazole Foam 2% treatment for dermatitis in younger patients. The company has commenced shipping of the product and has 180 days of marketing exclusivity.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs